{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:07:07Z","timestamp":1768255627247,"version":"3.49.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tuberculosis (TB) treatment relies on a prolonged first-line antibiotic regimen, including isoniazid, rifampicin (RF), ethambutol (EMB), and pyrazinamide.<\/jats:p>\n                    <jats:p>Pharmacogenetics plays a crucial role in optimizing TB treatment by addressing individual variability in drug metabolism and responses. Genetic polymorphisms can significantly affect pharmacokinetics and therapeutic outcomes. The aim of this review was to explore the role of pharmacogenetics in first-line antibiotics used to treat TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We reviewed the literature using PubMed, Scopus, Web of Science, and the Cochrane Library, focusing on articles published in the last 10 years (from December 2014 to December 2024) on the pharmacogenetics of first-line anti-TB drugs. Only English-language studies involving human subjects were included, prioritizing those investigating genetic variants that affect drug bioavailability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this study, 33 manuscripts were included.<\/jats:p>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">N-acetyltransferase 2<\/jats:italic>\n                      Single-nucleotide polymorphisms were associated with different isoniazid acetylation rates, which affect toxicity and efficacy. Genetic variations in\n                      <jats:italic toggle=\"yes\">CYP2E1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">GSTM1<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">MnSOD<\/jats:italic>\n                      also contribute to hepatotoxicity.\n                    <\/jats:p>\n                    <jats:p>\n                      For RF, variants in\n                      <jats:italic toggle=\"yes\">SLCO1B1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">PXR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CAR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CES1<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">CES2<\/jats:italic>\n                      genes were related to variability in drug absorption, metabolism, and clearance, highlighting the need for personalized dosing strategies. Notably,\n                      <jats:italic toggle=\"yes\">SLCO1B1<\/jats:italic>\n                      rs4149056 polymorphism is associated with decreased OATP1B1 RF transport activity, potentially leading to increased plasma exposure, whereas other polymorphisms modulate drug exposure and clearance rates. In addition, sex, body weight, and genotype influenced RF pharmacokinetics, suggesting the need for tailored dosing recommendations based on patient characteristics.\n                    <\/jats:p>\n                    <jats:p>\n                      Similarly, variability in EMB pharmacokinetics is associated with\n                      <jats:italic toggle=\"yes\">CYP1A2<\/jats:italic>\n                      2159, which is related to a 50% reduction in bioavailability, necessitating dose adjustments in patients coinfected with TB and HIV. Some variants of\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">OATP1B1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">PXR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">VDR<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP24A1<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">CYP27B1<\/jats:italic>\n                      may further modulate the plasma and intracellular concentrations of EMB, thereby influencing drug efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This review highlights the importance of integrating pharmacogenetic insights into clinical practice to enhance the efficacy of TB treatment, minimize toxicity, and prevent drug resistance. Despite promising evidence, further research and clinical validation are required to implement pharmacogenetics in routine TB management. Future advancements in therapeutic drug monitoring and omics technologies will pave the way for precision medicine in TB therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001378","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T01:02:29Z","timestamp":1756947749000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenetics of First-Line Antitubercular Drugs: An Update"],"prefix":"10.1097","volume":"48","author":[{"given":"Alessandra","family":"Manca","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-9694","authenticated-orcid":false,"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1186\/s12889-024-21019-1","article-title":"The asymptomatic tuberculosis proportion among the elderly population: a systematic review and meta-analysis","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Public Health"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","article-title":"Latent tuberculosis infection: an overview","volume":"43","author":"Kiazyk","year":"2017","journal-title":"Can Commun Dis Rep"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1002\/mco2.353","article-title":"Mycobacterium tuberculosis: pathogenesis and therapeutic targets","volume":"4","author":"Yang","year":"2023","journal-title":"MedComm (2020)"},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fmb.14.70","article-title":"Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development","volume":"9","author":"Le Chevalier","year":"2014","journal-title":"Future Microbiol"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.analchem.4c04166","article-title":"Development and comprehensive evaluation of culture-independent, long amplicon-based targeted next-generation sequencing methods for predicting antimicrobial resistance in tuberculosis","volume":"97","author":"Zhang","year":"2025","journal-title":"Anal Chem"},{"key":"R6-20260108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF03256649","article-title":"The role of DOTS in tuberculosis treatment and control","volume":"2","author":"Davies","year":"2003","journal-title":"Am J Respir Med"},{"key":"R7-20260108","first-page":"1310","article-title":"Therapeutic strategies for tuberculosis: progress and lessons learned","volume":"37","author":"Sun","year":"2024","journal-title":"Biomed Environ Sci"},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/ijmy.ijmy_164_24","article-title":"Pyrazinamide resistance: a major cause of switching shorter to longer bedaquiline-based regimens in multidrug-resistant tuberculosis patients","volume":"13","author":"Putra","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1186\/s12879-024-10339-7","article-title":"Predictors of treatment delay among drug resistant tuberculosis patients in Uganda","volume":"24","author":"Kasozi","year":"2024","journal-title":"BMC Infect Dis"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-0042-1743567","article-title":"Genetic variants and drug efficacy in tuberculosis: a step toward personalized therapy","volume":"9","author":"Khan","year":"2022","journal-title":"Glob Med Genet"},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2016.02.003","article-title":"Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: a comparison of the reactivity of isoniazid with its known human metabolites","volume":"106","author":"Khan","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/dna.1990.9.193","article-title":"Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression","volume":"9","author":"Blum","year":"1990","journal-title":"DNA Cell Biol"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/hmg\/9.16.2435","article-title":"An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes","volume":"9","author":"Sim","year":"2000","journal-title":"Hum Mol Genet"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HMER.S290542","article-title":"Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia","volume":"13","author":"Molla","year":"2021","journal-title":"Hepat Med"},{"key":"R16-20260108","first-page":"1172","article-title":"Anti-TB drug concentrations and drug-associated toxicities among TB\/HIV-coinfected patients","volume":"72","author":"Sekaggya-Wiltshire","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12879-018-3230-6","article-title":"Toxicity associated with tuberculosis chemotherapy in the REMoxTB study","volume":"18","author":"Tweed","year":"2018","journal-title":"BMC Infect Dis"},{"key":"R18-20260108","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial rna polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"R19-20260108","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jiph.2018.04.005","article-title":"Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis","volume":"11","author":"Zaw","year":"2018","journal-title":"J Infect Public Health"},{"key":"R20-20260108","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/0115734064260853230926080134","article-title":"An overview of various rifampicin analogs against Mycobacterium tuberculosis and their drug interactions","volume":"20","author":"Asif","year":"2024","journal-title":"Med Chem"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1006\/bbrc.2000.2902","article-title":"Induction of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes","volume":"273","author":"Runge","year":"2000","journal-title":"Biochem Biophysical Res Commun"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00228-024-03749-8","article-title":"Therapeutic drug monitoring in tuberculosis","volume":"80","author":"Sarkar","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/jb.84.5.1099-1103.1962","article-title":"Mode of action of ethambutol","volume":"84","author":"Forbes","year":"1962","journal-title":"J Bacteriol"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"MGM2","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol Spectr"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1665-2681(19)31302-X","article-title":"Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population","volume":"12","author":"Gupta","year":"2013","journal-title":"Ann Hepatol"},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jcma.2014.01.010","article-title":"Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury","volume":"77","author":"Huang","year":"2014","journal-title":"J Chin Med Assoc"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13318-024-00910-7","article-title":"Precision medicine strategies to improve isoniazid therapy in patients with tuberculosis","volume":"49","author":"Thomas","year":"2024","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0091270007303768","article-title":"A pharmacogenomics primer","volume":"47","author":"Court","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"e00210-17","DOI":"10.1128\/AAC.00210-17","article-title":"Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/toxsci\/54.1.19","article-title":"Localization of N-acetyltransferases NAT1 and NAT2 in human tissues","volume":"54","author":"Windmill","year":"2000","journal-title":"Toxicol Sci"},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"e70040","DOI":"10.1002\/prp2.70040","article-title":"The N-Acetyltransferase 2 polymorphism and susceptibility to inflammatory bowel disease: a case-control study","volume":"13","author":"Petryszyn","year":"2025","journal-title":"Pharmacol Res Perspect"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-007-0305-5","article-title":"The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid","volume":"63","author":"Donald","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R39-20260108","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12863-024-01286-y","article-title":"Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis","volume":"25","author":"Mahajan","year":"2024","journal-title":"BMC Genom Data"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/ijmy.ijmy_106_24","article-title":"Pharmacogenetic study of drugs affecting Mycobacterium tuberculosis","volume":"13","author":"Shabani","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"R41-20260108","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1164\/rccm.202309-1583OC","article-title":"A nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing","volume":"209","author":"Verma","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/cid\/ciac001","article-title":"Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without human immunodeficiency virus (HIV) exposure","volume":"75","author":"Beranger","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R43-20260108","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12879-024-09638-w","article-title":"Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection","volume":"24","author":"Cho","year":"2024","journal-title":"BMC Infect Dis"},{"key":"R44-20260108","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1478-3231.2011.02697.x","article-title":"TNF-\u03b1 genetic polymorphism -308G\/A and antituberculosis drug-induced hepatitis","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int"},{"key":"R45-20260108","first-page":"34","article-title":"HLA-DQ B1*0201 and A1*0102 alleles are not responsible for antituberculosis drug-induced hepatotoxicity risk in Spanish population","volume":"3","author":"Leiro-Fernandez","year":"2016","journal-title":"Front Med (Lausanne)"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"e0213718","DOI":"10.1371\/journal.pone.0213718","article-title":"High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre","volume":"14","author":"Seijger","year":"2019","journal-title":"PLoS One"},{"key":"R48-20260108","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R49-20260108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy026","article-title":"The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R50-20260108","doi-asserted-by":"crossref","first-page":"134748","DOI":"10.1016\/j.ijbiomac.2024.134748","article-title":"Human organic anion transporting polypeptide 1B3 (OATP1B3) is more heavily N-glycosylated than OATP1B1 in extracellular loops 2 and 5","volume":"278","author":"Liang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"R51-20260108","doi-asserted-by":"crossref","first-page":"107034","DOI":"10.1016\/j.ijantimicag.2023.107034","article-title":"Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: effects of SLCO1B1 polymorphisms on drug exposure","volume":"63","author":"Hoa","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"R52-20260108","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.ge.29.120195.003135","article-title":"Genetic analysis of the multidrug transporter","volume":"29","author":"Gottesman","year":"1995","journal-title":"Annu Rev Genet"},{"key":"R53-20260108","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R54-20260108","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1073\/pnas.93.9.4001","article-title":"P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans","volume":"93","author":"Schuetz","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R55-20260108","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R56-20260108","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/mol.65.3.496","article-title":"Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver","volume":"65","author":"Jinno","year":"2004","journal-title":"Mol Pharmacol"},{"key":"R57-20260108","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/FPC.0000000000000552","article-title":"Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort","volume":"35","author":"Amorim","year":"2025","journal-title":"Pharmacogenet Genomics"},{"key":"R58-20260108","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/pharmaceutics16030388","article-title":"Exploring variability in rifampicin plasma exposure and development of anti-tuberculosis drug-induced liver injury among patients with pulmonary tuberculosis from the pharmacogenetic perspective","volume":"16","author":"Kivrane","year":"2024","journal-title":"Pharmaceutics"},{"key":"R59-20260108","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/23744235.2024.2309348","article-title":"Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis","volume":"56","author":"Sileshi","year":"2024","journal-title":"Infect Dis (Lond)"},{"key":"R60-20260108","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/jac\/dkt036","article-title":"Relationship between CES2 genetic variations and rifampicin metabolism","volume":"68","author":"Song","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R61-20260108","doi-asserted-by":"crossref","first-page":"e01583-19","DOI":"10.1128\/AAC.01583-19","article-title":"Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients coinfected with tuberculosis and HIV","volume":"64","author":"Sundell","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R62-20260108","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijpharm.2015.11.044","article-title":"Ethambutol plasma and intracellular pharmacokinetics: a pharmacogenetic study","volume":"497","author":"Fatiguso","year":"2016","journal-title":"Int J Pharm"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:01:46Z","timestamp":1767848506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001378","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"2025-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}